Business1 min read

Lilly raises outlook for third time this year as Zepbound sales soar.

By · Via MarketWatch Top Stories · Published by Everything Blog

In short

Eli Lilly updated its financial outlook for the third time this year due to exceptional revenue momentum. This revision stems entirely from soaring sales of its popular weight-loss drug, Zepbound. The treatment currently maintains a dominant position across the prescription weight-loss landscape in the United States.

Key points

  • Repeated guidance upgrades demonstrate the exceptionally strong financial impact of the d…: Repeated guidance upgrades demonstrate the exceptionally strong financial impact of the drugmaker's metabolic treatments.
  • Robust consumer demand for Zepbound is successfully driving overall corporate growth this…: Robust consumer demand for Zepbound is successfully driving overall corporate growth this year.
  • Eli Lilly maintains a commanding market share over competitors in the American prescripti…: Eli Lilly maintains a commanding market share over competitors in the American prescription weight-loss sector.

The drug continues do dominate the market for prescription weight-loss drugs in the U.S.

Business